CN114469883A - Aminobutyric acid and vitamin C tablet for treating piglet scurvy, preparation method and application - Google Patents
Aminobutyric acid and vitamin C tablet for treating piglet scurvy, preparation method and application Download PDFInfo
- Publication number
- CN114469883A CN114469883A CN202011165041.8A CN202011165041A CN114469883A CN 114469883 A CN114469883 A CN 114469883A CN 202011165041 A CN202011165041 A CN 202011165041A CN 114469883 A CN114469883 A CN 114469883A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- aminobutyric acid
- scurvy
- piglet
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 174
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 87
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 87
- 239000011718 vitamin C Substances 0.000 title claims abstract description 87
- 229940124277 aminobutyric acid Drugs 0.000 title claims abstract description 73
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 206010047623 Vitamin C deficiency Diseases 0.000 title claims abstract description 71
- 208000010233 scurvy Diseases 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000853 adhesive Substances 0.000 claims abstract description 21
- 230000001070 adhesive effect Effects 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 20
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 238000000576 coating method Methods 0.000 claims abstract description 14
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 238000009475 tablet pressing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 5
- 235000013343 vitamin Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 229940088594 vitamin Drugs 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 235000021050 feed intake Nutrition 0.000 abstract description 4
- 230000006996 mental state Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 201000003102 mental depression Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010018291 Gingival swelling Diseases 0.000 description 2
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
Abstract
The invention belongs to the technical field of animal husbandry and veterinary medicine, and discloses a aminobutyric acid and vitamin C tablet for treating piglet scurvy, a preparation method and application, wherein the tablet is prepared by uniformly mixing aminobutyric acid, vitamin C, an adhesive, a disintegrating agent and a lubricating agent, tabletting and coating; the obtained aminobutyric acid vitamin C tablet can be used for treating swine scurvy. According to the invention, through adding the aminobutyric acid and the vitamins in a proper proportion, the feed intake of piglets is increased by using the aminobutyric acid, the piglet mental state is restored, so that the vitamins are better absorbed, the medicinal value is exerted, the absorption and utilization of the aminobutyric acid are promoted by using the vitamin C, the feed intake is further increased, the piglet restoration is accelerated, the two supplement each other, the opposite side is promoted to exert a greater effect, and the treatment course of scurvy is effectively shortened.
Description
Technical Field
The invention belongs to the technical field of animal husbandry and veterinary medicine, and relates to a vitamin C tablet, in particular to a aminobutyric acid vitamin C tablet for treating piglet scurvy, a preparation method and application.
Background
Due to the fact that the nutritional ingredients of the daily ration for the pigs are incomplete, in the growing process of the pigs, particularly when piglets are affected by external stimulation and the like, phenomena of appetite reduction, mental depression or excitation and the like easily occur, so that the piglets are unbalanced in nutrition intake, and are suffered from scurvy, symptoms of mental depression, weakness, anorexia, gum swelling, bleeding, osteoarticular muscle pain and the like when the piglets are serious. The existing methods for treating the scurvy all adopt forced administration of vitamin C, but the forced action can further aggravate the stress reaction of piglets, reduce the dietary intake and prolong the course of treatment of the scurvy.
Disclosure of Invention
The invention aims to provide a aminobutyric acid vitamin C tablet for treating piglet scurvy so as to shorten the treatment course of piglet scurvy;
the invention also aims to provide a preparation method of the aminobutyric acid vitamin C tablets for treating piglet scurvy;
the invention also aims to provide application of the aminobutyric acid vitamin C tablets for treating piglet scurvy.
In order to achieve the purpose, the invention adopts the technical scheme that:
a aminobutyric acid vitamin C tablet for treating piglet scurvy comprises the following raw materials of effective components in parts by weight: 40-100 parts of aminobutyric acid, 8-30 parts of vitamin C, 810-937 parts of adhesive, 5-10 parts of lubricant and 10-50 parts of disintegrating agent.
The adhesive is prepared from microcrystalline cellulose and lactose according to a weight ratio of 446-503: 307 to 491, respectively.
As another limitation, the lubricant is magnesium stearate, talc, or polyethylene glycol 4000.
As a third limitation, the disintegrant is a mixture of sodium carboxymethyl starch and croscarmellose sodium in a weight ratio of 1-8: 1-2.
The invention also provides a preparation method of the aminobutyric acid vitamin C tablets for treating piglet scurvy, which comprises the following steps of:
1) three times of mixing treatment
Uniformly mixing aminobutyric acid, vitamin C and an adhesive for the first time, then adding a disintegrating agent for secondary uniform mixing, then adding a lubricating agent for tertiary uniform mixing, and obtaining powder M;
2) tabletting and coating
Tabletting and coating the powder M to obtain the aminobutyric acid and vitamin C tablets for treating piglet scurvy.
The adhesive is divided into a first part adhesive accounting for 10-20% of the total using amount of the adhesive and a second part adhesive accounting for the rest amount;
the first mixing is to take the aminobutyric acid and the vitamin C to be mixed with the first part of the adhesive for the first time, and then to be mixed with the second part of the adhesive for the second time.
As another limitation, after the second time of uniform mixing, the time of uniform mixing is 15-30 min;
uniformly mixing for the second time for 5-10 min;
and uniformly mixing for the third time for 15-30 min.
As a third limitation, the coating is made of ethyl cellulose or hydroxypropyl methyl cellulose, and the solvent is 80% ethanol solution.
As a fourth limitation, in the step 2), the pressing force is 150-180N.
The invention also provides application of the aminobutyric acid vitamin C tablets for treating piglet scurvy as a medicament for treating piglet scurvy.
Due to the adoption of the technical scheme, compared with the prior art, the invention has the technical progress that:
the invention obtains the aminobutyric acid vitamin C tablets which are applied to piglets and have proper medicinal dosage through a large number of experiments and are used for treating piglet scurvy. According to the invention, through adding the aminobutyric acid and the vitamins in a proper proportion, the aminobutyric acid is utilized to promote the vitamins to be better absorbed, and a greater medicinal value is exerted, so that the treatment course of the piglet scurvy is shortened;
aminobutyric acid (Aminobutric acid) has the effects of reducing blood ammonia and promoting brain metabolism, can enhance glucose phosphatase activity, promote phospholipid absorption and brain protein synthesis, regulate neurotransmitter balance in brain, enable tissue metabolism activity to be vigorous, improve blood circulation, increase brain blood flow, enhance brain perfusion, enhance the anti-hypoxia capability of nerve cells and restore the brain cell function; the aminobutyric acid is also a central medium, has the effects of improving the functions of the central nervous system, activating, protecting and repairing nerve cells and the like, can promote cerebral metabolism, and improves and reduces the depression condition of animals; the aminobutyric acid reduces the involuntary movement of the piglets by regulating neurotransmitter, thereby reducing energy consumption, promoting the secretion of gastric juice of the piglets, increasing the feed intake of the piglets, recovering the mental state of the piglets and further being beneficial to the recovery of various hormone levels of the bodies. Meanwhile, the aminobutyric acid also contributes to the absorption and utilization of the vitamin C. Vitamin C can participate in amino acid metabolism, formation of neurotransmitter, collagen and interstitial tissue of histiocytes, and has stronger antioxidant capacity. The vitamin C can enhance the anti-stress capability of the organism to the outside and improve the immunity. The vitamin C can promote the absorption and utilization of the aminobutyric acid, further increase the feed intake and accelerate the recovery of piglets, and the vitamin C and the aminobutyric acid supplement each other to promote the opposite side to play a greater role and effectively shorten the treatment course of the scurvy;
by adding aminobutyric acid and vitamin C in a proper proportion, the traditional Chinese medicine composition can treat scurvy, increase the immunity of an organism, protect the liver, promote the growth of the organism, improve the metabolic level of animals, accelerate blood flow operation, promote body recovery, improve the production performance of the animals and effectively shorten the course of treatment of scurvy;
the aminobutyric acid vitamin C tablet for treating the piglet scurvy can treat scurvy, improve the utilization rate of feed, improve the immunity and oxidation resistance of organisms, promote the growth of piglets and improve the quality of the piglets;
the preparation method disclosed by the invention is simple in process, the aminobutyric acid is beneficial to maintaining the acidity of the tablet, so that the stability of the vitamin C is further guaranteed, the vitamin C is prevented from being oxidized, and the prepared aminobutyric acid vitamin C tablet for treating piglet scurvy is safe and controllable;
furthermore, the aminobutyric acid vitamin C tablet for treating piglet scurvy adopts dry direct tabletting, and then the tablet is coated, so that the vitamin C can be further protected from oxidative deterioration;
the invention has wide raw material source and low cost, and can bring good economic benefit for breeding enterprises.
The aminobutyric acid vitamin C tablet for treating the piglet scurvy is suitable for being directly fed to piglets to treat the piglet scurvy and promote the growth of the piglets.
Detailed Description
The present invention is further illustrated by the following specific examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure.
Example 1 preparation method of a vitamin C aminobutyric acid tablet for treating piglet scurvy
The embodiment prepares the aminobutyric acid and vitamin C tablets for treating the piglet scurvy, which sequentially comprises the following steps:
1) three times of mixing treatment
40kg of aminobutyric acid and 10kg of vitamin C are taken, 46kg of microcrystalline cellulose and 47kg of lactose (recorded as a first part of adhesive) are added, the mixture is stirred for 3min and uniformly mixed for the first time, 414kg of microcrystalline cellulose and 423kg of lactose (recorded as a second part of adhesive) are added, the mixture is stirred for 15min and uniformly mixed for the second time, 5kg of sodium carboxymethyl starch and 10kg of cross-linked sodium carboxymethyl cellulose are added, the mixture is stirred for 5min and uniformly mixed for the second time, and then 5kg of magnesium stearate is added, the mixture is stirred for 16min and uniformly mixed for the third time, so that powder M1 is obtained.
2) Tabletting and coating
Adding ethyl cellulose as a coating material into an 80% ethanol solution, stirring and dispersing uniformly to prepare a coating solution with the concentration of 5%.
And pressing the powder M1 into tablets by a tablet press, controlling the force to be 150N, adding the obtained plain tablets into a coating machine, slowly rotating a coating pan, spraying coating liquid on the surfaces of the plain tablets in an atomizing manner to dry into films after the plain tablets are preheated, and obtaining the aminobutyric acid vitamin C tablets for treating piglet scurvy, which are marked as N1.
The stability of the vitamin C is not too high and the vitamin C is easy to oxidize and decompose, so that the aminobutyric acid vitamin C tablet for treating the piglet scurvy has good stability by adopting the aminobutyric acid and the vitamin C to be matched, the vitamin C is effectively prevented from being oxidized, and the vitamin C is further prevented from being oxidized through coating.
The aminobutyric acid vitamin C tablets for treating the piglet scurvy are suitable for being directly fed to piglets to treat the piglet scurvy and promote growth.
Example 2-6 preparation method of aminobutyric acid vitamin C tablets for treating piglet scurvy
Examples 2 to 6 are methods for preparing a aminobutyric acid vitamin C tablet for treating piglet scurvy, which have the same steps as example 1 except for the differences in raw material dosage and process parameters, and are specifically shown in table 1:
TABLE 1 summary of the process parameters of examples 2 to 6
The contents of the other portions of examples 2 to 6 are the same as those of example 1.
EXAMPLE 7 results of assay of L-aminobutyric acid vitamin C tablets for treating piglet scurvy
And calculating the labeled amount of the corresponding raw material according to the content of the raw material/the using amount of the corresponding raw material in the obtained tablet, and controlling the labeled amount of the aminobutyric acid and the vitamin C to be 90.0-110.0%. The appearance, content and disintegration time of the aminobutyric acid vitamin C tablets N1-N6 for treating piglet scurvy prepared in the examples 1-6 are measured, and specific results are shown in a table 2:
TABLE 2 summary of the quality test results of vitamin C aminobutyric acid tablets for treating piglet scurvy prepared in examples 1 to 6
As can be seen from Table 2, the aminobutyric acid and vitamin C tablets N1-N6 for treating piglet scurvy prepared in examples 1-6 are complete and smooth in appearance, uniform in color, free of foreign matters and speckles, and qualified in disintegration time limit, and the contents of aminobutyric acid and vitamin C in the tablets meet the standards.
EXAMPLE 8 stability test of L-aminobutyric acid vitamin C tablets for treating piglet scurvy
The stability detection of the aminobutyric acid vitamin C tablets N1-N6 for treating the piglet scurvy and the common commercially available vitamin C tablets prepared in the examples 1-6 is carried out by the following specific detection method:
the accelerated test is placed for 12 months under the conditions that the temperature is 40 +/-2 ℃ and the relative humidity is 75 +/-5%, samples are respectively taken at the end of 0 month, 1 month, 2 months, 3 months, 6 months and 12 months during the test period, the corresponding labeled amount of the aminobutyric acid and the vitamin C is detected, and the corresponding labeled amount of the aminobutyric acid and the vitamin C is controlled to be 90.0-110.0%. Specific detection results are shown in table 3:
TABLE 3 stability test results of aminobutyric acid vitamin C tablets N1-N6 for treating piglet scurvy and common commercially available vitamin C tablets
As can be seen from table 3, the vitamin C aminobutyric acid tablets N1 to N6 for treating piglet scurvy prepared in examples 1 to 6 have no obvious change in each index and good quality stability through an accelerated test, while the common commercially available vitamin C tablets have a yellow appearance and an uneven color after the accelerated test, and the labeled amount of vitamin C is gradually reduced along with the time of the accelerated test. The experiments prove that the aminobutyric acid vitamin C tablets for treating piglet scurvy prepared by the invention have good stability, and are superior to common commercially available vitamin C tablets.
Example 9 application of vitamin C aminobutyric acid tablets for treating piglet scurvy
The scurvy piglets are mainly manifested by mental depression, weakness, anorexia, gum swelling, bleeding, bone joint muscle pain, skin stasis, ecchymosis, hair follicle hyperkeratosis, peripheral bleeding, weight loss, bad state and poor appetite.
The test is carried out in a certain pig farm of Shijiazhuang, the piglets of the batch have the symptoms of skin ecchymosis, subcutaneous hemorrhage, leg stiffness and the like, and are diagnosed by local veterinarians by combining clinical symptoms and vitamin detection, so that the scurvy caused by the lack of vitamin C is obtained. 80 sick piglets are selected and randomly divided into 8 groups, 10 piglets in each group are respectively a blank group, a control group and SN 1-SN 6 groups, wherein common feed and drinking water are given to the blank group, commercially available common vitamin C tablets (oral administration, the vitamin C equivalent dose is 0.8g) and common feed and drinking water are given to the control group, and the SN 1-SN 6 groups are correspondingly given with a aminobutyric acid vitamin C tablet (oral administration, the vitamin C equivalent dose is 0.8g) and common feed and drinking water for treating piglet scurvy one by one, and the continuous test is carried out until scurvy symptoms completely disappear or 14 days end.
The weight gain and the scurvy condition of the piglets are observed every day during the test period and are counted, and the specific results are shown in the following table:
TABLE 4 summary of the application effect of vitamin C aminobutyric acid tablets for treating piglet scurvy and promoting piglet growth
As can be seen from Table 4, compared with the control group, the weight of the SN 1-SN 6 group and the control group is increased, the symptom of the scurvy is reduced or eliminated, the mental state is good, the weight of the blank group of piglets is reduced, the scurvy is aggravated, and even the piglets die, and the effect of treating the scurvy of the piglets and promoting the growth of the piglets is proved by the aminobutyric acid vitamin C tablets for treating the scurvy of the piglets. The recovery time of the piglets of the SN 1-SN 6 groups is obviously shorter than that of the control group, and the cure rate is higher than that of the control group, so that the aminobutyric acid vitamin C tablets for treating the piglet scurvy can effectively shorten the treatment course of scurvy.
Claims (10)
1. The aminobutyric acid vitamin C tablet for treating piglet scurvy is characterized by comprising the following raw materials of effective components in parts by weight: 40-100 parts of aminobutyric acid, 8-30 parts of vitamin C, 810-937 parts of adhesive, 5-10 parts of lubricant and 10-50 parts of disintegrating agent.
2. The vitamin C aminobutyric acid tablet for treating piglet scurvy is characterized in that the adhesive is prepared from microcrystalline cellulose and lactose according to a weight ratio of 446-503: 307 to 491, respectively.
3. The vitamin C aminobutyric acid tablet for treating piglet scurvy as claimed in claim 1, wherein said lubricant is magnesium stearate, talc or polyethylene glycol 4000.
4. The vitamin C aminobutyric acid tablet for treating piglet scurvy is characterized in that the disintegrating agent is prepared from sodium carboxymethyl starch and croscarmellose sodium in a weight ratio of 1-8: 1-2.
5. The preparation method of the vitamin C aminobutyric acid tablets for treating the piglet scurvy is characterized by comprising the following steps of sequentially carrying out:
1) three times of mixing treatment
Uniformly mixing aminobutyric acid, vitamin C and an adhesive for the first time, then adding a disintegrating agent for secondary uniform mixing, then adding a lubricating agent for tertiary uniform mixing, and obtaining powder M;
2) tabletting and coating
Tabletting and coating the powder M to obtain the aminobutyric acid and vitamin C tablets for treating piglet scurvy.
6. The preparation method of the vitamin C aminobutyric acid tablet for treating the piglet scurvy is characterized in that the adhesive is divided into a first part adhesive accounting for 10-20% of the total amount of the adhesive and a second part adhesive in the balance;
the first mixing is to take the aminobutyric acid and the vitamin C to be mixed with the first part of the adhesive for the first time, and then to be mixed with the second part of the adhesive for the second time.
7. The method for preparing the vitamin C aminobutyric acid tablet for treating the piglet scurvy according to the claim 5 or 6,
after the second time of uniform mixing, the time for uniform mixing is 15-30 min;
uniformly mixing for the second time for 5-10 min;
and uniformly mixing for the third time for 15-30 min.
8. The method for preparing the vitamin C aminobutyric acid tablet for treating the piglet scurvy is characterized in that the coating is made of ethyl cellulose or hydroxypropyl methyl cellulose and the solvent is 80% ethanol solution.
9. The preparation method of the vitamin C aminobutyric acid tablet for treating piglet scurvy as claimed in claim 5 or 6, wherein in the step 2), the tablet pressing force is 150-180N.
10. The use of the vitamin C aminobutyric acid tablets for treating piglet scurvy as claimed in any one of claims 1 to 4, as a medicament for treating piglet scurvy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011165041.8A CN114469883A (en) | 2020-10-27 | 2020-10-27 | Aminobutyric acid and vitamin C tablet for treating piglet scurvy, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011165041.8A CN114469883A (en) | 2020-10-27 | 2020-10-27 | Aminobutyric acid and vitamin C tablet for treating piglet scurvy, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114469883A true CN114469883A (en) | 2022-05-13 |
Family
ID=81471530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011165041.8A Pending CN114469883A (en) | 2020-10-27 | 2020-10-27 | Aminobutyric acid and vitamin C tablet for treating piglet scurvy, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114469883A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443534A (en) * | 2002-03-13 | 2003-09-24 | 北京英惠尔生物技术有限公司 | Production method of coated vitamin C preparation used in animal feed |
| CN106361775A (en) * | 2016-08-29 | 2017-02-01 | 吉安市御美丽健康产业股份有限公司 | Nutrient for adult female and preparation method of nutrient |
| CN108347990A (en) * | 2015-10-16 | 2018-07-31 | 诺维克斯科学私人有限公司 | The stabilization composition of vitamin C and zinc metal sheet agent |
-
2020
- 2020-10-27 CN CN202011165041.8A patent/CN114469883A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443534A (en) * | 2002-03-13 | 2003-09-24 | 北京英惠尔生物技术有限公司 | Production method of coated vitamin C preparation used in animal feed |
| CN108347990A (en) * | 2015-10-16 | 2018-07-31 | 诺维克斯科学私人有限公司 | The stabilization composition of vitamin C and zinc metal sheet agent |
| CN106361775A (en) * | 2016-08-29 | 2017-02-01 | 吉安市御美丽健康产业股份有限公司 | Nutrient for adult female and preparation method of nutrient |
Non-Patent Citations (7)
| Title |
|---|
| 张秀美主编: "《兽医科学用药手册》", 30 June 2018, 山东科学技术出版社 * |
| 李小强等: ""抗热应激制剂对猪生长性能和消化率的影响"", 《畜牧科技》 * |
| 李文婷等: ""γ-氨基丁酸在养猪生产中的应用研究进展"", 《养猪》 * |
| 福建倍思达生物有限公司: "《https://www.qybz.org.cn/usercenter/pdfDetail/272334》", 23 November 2016 * |
| 药学教研组: "《药剂士专业试用教材 药剂学》", 31 December 1975 * |
| 郑秋红等: ""抗热应激饲料添加剂对猪生长性能的影响及作用机理研究"", 《江西农业学报》 * |
| 鄢海燕主编: "《高职高专"十三五"规划教材 药剂学 第2版》", 31 January 2018, 江苏凤凰科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101502306B (en) | Bee product composition and preparation method thereof | |
| WO2014187196A1 (en) | Biogas residue-containing feed additive for dairy cattle | |
| CN102302211A (en) | Health-care beverage | |
| CN113142398A (en) | Functional feed additive for ruminants and preparation method thereof | |
| CN103493983B (en) | Feed additive for improving fur quality of fur-bearing animal and manufacturing method thereof | |
| WO2014183508A1 (en) | Biogas residue-containing formula feed for chicken | |
| CN104286818B (en) | A kind of salad dressing containing Pollen Maydis and preparation method thereof | |
| CN110664896B (en) | Anti-stress sudden death prevention compound fermentation traditional Chinese medicine additive and preparation method and application thereof | |
| RU2355164C1 (en) | Method for production of honey with higher biological activity | |
| CN108378355A (en) | Reducing diabetes B patient's postprandial blood sugar improves the alimentation composition pre- before the meal and preparation method thereof that blood fat increases intestinal beneficial bacterium | |
| CN114469883A (en) | Aminobutyric acid and vitamin C tablet for treating piglet scurvy, preparation method and application | |
| CN116762954A (en) | Health food for improving immunity and preparation method thereof | |
| CN108095102B (en) | A composition for improving energy supply and enhancing energy metabolism | |
| CN110506847A (en) | A kind of pet nutrition replenishers and its preparation method and application | |
| CN102823778B (en) | Functional feed additive special for experimental miniature pig | |
| CN110742269A (en) | Memory enhancing composition suitable for postpartum women and preparation method thereof | |
| CN114176170B (en) | Functional feed additive and preparation method and application thereof | |
| CN101480412A (en) | Honeybee four-treasure for treating prostatosis | |
| CN108660174B (en) | Sesame bioactive peptide for resisting fatigue and promoting intestinal probiotic proliferation | |
| CN104872650A (en) | Tablets containing multiple vitamins and mineral substances suitable for children and teenagers | |
| CN112219903A (en) | Body-shaping and qi-tonifying milk powder for women and preparation method thereof | |
| CN111149918A (en) | Composition of green disease-free yield-increasing cultivation technology and application | |
| CN109170132A (en) | Improve the preparation method of the additive of pig appetite | |
| CN110236047A (en) | A kind of ferment drink of slim beauty and preparation method thereof | |
| KR102428974B1 (en) | Dietary composition for the prevention of obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |